# Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BLD-0409 in Healthy Subjects

> **NCT04146805** · PHASE1 · COMPLETED · sponsor: **Blade Therapeutics** · enrollment: 80 (actual)

## Conditions studied

- Chronic Liver Disease
- NASH - Nonalcoholic Steatohepatitis

## Interventions

- **DRUG:** BLD-0409
- **DRUG:** Control: Placebo

## Key facts

- **NCT ID:** NCT04146805
- **Lead sponsor:** Blade Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-10
- **Primary completion:** 2020-12-03
- **Final completion:** 2021-04-12
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2021-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04146805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04146805, "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BLD-0409 in Healthy Subjects". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04146805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*